quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·1d
PRRelease
Arcutis Biotherapeutics Inc. logo

Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

ARQT· Arcutis Biotherapeutics Inc.
Health Care
Original source

Companies

  • ARQT
    Arcutis Biotherapeutics Inc.
    Health Care

Recent analyst ratings

  • Jul 25UpdateGoldman$18.00
  • Dec 30UpdateH.C. Wainwright$19.00
  • Aug 28UpdateJefferies$15.00
  • Jan 3UpdateMizuho$8.00
  • Oct 26UpdateMizuho$4.00
  • Oct 13UpdateGoldman$6.00

Related

  • SEC2d
    SEC Form S-8 filed by Arcutis Biotherapeutics Inc.
  • SEC2d
    SEC Form DEFA14A filed by Arcutis Biotherapeutics Inc.
  • SEC2d
    SEC Form DEF 14A filed by Arcutis Biotherapeutics Inc.
  • PR8d
    Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
  • PR15d
    The Credibility Filter Wall Street Uses to Sort Biotech Winners
  • PR16d
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
  • INSIDER20d
    SEC Form 4 filed by Welgus Howard G.
  • PR23d
    Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022